Modulating antibody effector functions by Fc glycoengineering

Mikel García-Alija,Berre van Moer,Diego E Sastre,Tala Azzam,Jonathan J Du,Beatriz Trastoy,Nico Callewaert,Eric J Sundberg,Marcelo E Guerin
DOI: https://doi.org/10.1016/j.biotechadv.2023.108201
Abstract:Antibody based drugs, including IgG monoclonal antibodies, are an expanding class of therapeutics widely employed to treat cancer, autoimmune and infectious diseases. IgG antibodies have a conserved N-glycosylation site at Asn297 that bears complex type N-glycans which, along with other less conserved N- and O-glycosylation sites, fine-tune effector functions, complement activation, and half-life of antibodies. Fucosylation, galactosylation, sialylation, bisection and mannosylation all generate glycoforms that interact in a specific manner with different cellular antibody receptors and are linked to a distinct functional profile. Antibodies, including those employed in clinical settings, are generated with a mixture of glycoforms attached to them, which has an impact on their efficacy, stability and effector functions. It is therefore of great interest to produce antibodies containing only tailored glycoforms with specific effects associated with them. To this end, several antibody engineering strategies have been developed, including the usage of engineered mammalian cell lines, in vitro and in vivo glycoengineering.
What problem does this paper attempt to address?